Key result
Simple clinical score predicts no-reflow during primary PCI in STEMI with a ~0.73 c-statistic.
Why the study?
The ability to predict no-reflow phenomenon during PCI in STEMI patients using a simple pre-reperfusion risk score was needed.
Can a simple clinical risk score predict the development of no-reflow in STEMI patients undergoing primary or rescue PCI?
Observational (n=173)
Can a simple clinical risk score predict the development of no-reflow in STEMI patients undergoing primary or rescue PCI?
Effect estimate: c-statistics 0.734 (95% CI 0.654-0.814)
Absolute Event Rate: 46.7% vs 13.3%
A simple clinical risk score incorporating blood glucose, symptom-onset-to-balloon time, and lymphocyte count can efficiently predict the development of no-reflow in STEMI patients undergoing PCI.
Hypothesis-generating for no-reflow risk stratification in STEMI PCI; prospective validation needed before clinical adoption.
OBJECTIVES: To identify the STEMI patients at high risk in terms of no-reflow during percutaneous coronary intervention (PCI) with a simple risk score system that can be used before reperfusion. METHODS: Total 173 patients who had undergone primary or rescue percutaneous coronary intervention following the diagnosis of STEMI, were classified as "no-reflow" developers and "no-reflow" non-developers, during the procedure. The pre-procedural ECGs, laboratory parameters, demographic data, time for the treatment, and the treatment methods were evaluated with univariate analysis. The independent predictors were identified by multivariate logistic regression analysis among the no-reflow risk factors. Using the independent predictors, we developed a simple risk score system proportional to area under the ROC (AUROC) curves. RESULTS: The independent predictors of "no-reflow" phenomenon were identified as follows: high values of blood glucose at reference; long symptom-onset-to-balloon-time; and low lymphocyte count. The incidence rates of "no-reflow" in patients with low (0-1), moderate (2-3) and high (4-6) risk factors were 13.3%, 40.0%, and 46.7%, respectively. The risk score system demonstrated a good risk prediction between patients with various risk levels of the development of "no-reflow" with a c-statistics of 0.734 (95% CI 0.654-0.814). CONCLUSION: The development of "no-reflow" which is an adverse event in STEMI treatment can be predicted efficiently by simple clinical risk scoring method.
No takes yet. Share an insight, caveat, or question.
Doğan et al. (2015) conducted an observational in Acute STEMI (n=173). High clinical risk score (4-6 risk factors) vs. Low clinical risk score (0-1 risk factors) was evaluated on Development of no-reflow during PCI (c-statistics 0.734, 95% CI 0.654-0.814). A simple clinical risk score predicted the development of no-reflow during PCI in STEMI patients with a c-statistic of 0.734 (95% CI 0.654-0.814).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: